Sept. 12, 2023
Updated on Dec. 3, 2024, with trial phase advances and failures and the ability to get notifications. The entire dataset can be downloaded. Previous articles describe the bet that amylin can rival GLP-1 as the next big obesity target; a strategy involving gene silencing; efforts to preserve muscle. Also available in a single report: our award-winning Obesity Revolution.
The blazing success of weight loss drugs like Wegovy and Mounjaro has electrified the pursuit of new treatments for obesity. For now, Novo Nordisk and Eli Lilly are leading the market with injectable drugs that target receptors of the GLP-1 hormone to mimic the hormone’s effects of helping people feel full. But dozens of companies are also jumping into the race, seeing the potential to make millions of dollars if they can bring to market medications that are oral, longer-lasting, avoid side effects, or provide additional benefits besides weight loss.
Some 150 drugs are now in the tracker. Many of these drugs are also targeting receptors of GLP-1, as well as other hormones involved in satiety and metabolism, but some are using entirely novel mechanisms.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Authors
To submit a correction request, please visit our Contact Us page.
